22 October 2018 - The Global Antibody
Drugs Market is expected to grow at an exponential CAGR in the
years to come due to augmenting applications and scope across the globe.
Antibody Drugs are extensively employed for therapeutic purposes. The most
striking features associated with the use of these antibody drugs may include
less adverse effects, specificity, huge production, and homogeneity. Moreover,
it has been observed that the government has been taking various steps to
guarantee effective and secure production of protein therapeutics. The
biopharmaceutical manufacturers have also been offered protein drugs of lower
costs and high quality. Due to rising prerequisites and benefits across the
globe, the product is gaining huge recognition.
The
factors that are responsible for the robust Antibody Drugs market growth may
include augmented benefits, burgeoning demands for personalized medicine among
the customers, rising advancement of therapeutic antibodies to offer targeted
therapies, implementation of government initiatives, rise in the research and
development activities, and product innovations.
Global
Antibody Drugs Market is segregated on the basis of drug type as Antibody-Drugs
Conjugates, Polyclonal Antibodies, Monoclonal Antibodies, and others. Among all
the drug types, the Monoclonal Antibodies segment is holding the largest share
in the market. Antibody Drugs Market is segmented by application as Cancer and
Autoimmune Disorders, Cardiovascular Diseases, Central Nervous System (CNS)
Disorders, and others. As far as the application segmentation goes, the Cancer
segment is taking up the largest share in the market.
Antibody
Drugs Market is segregated on the basis of end user as Clinics, Hospitals,
Long-Term Care Facilities, Research Institutes, Healthcare Institutes, and others.
Among all the end users, it has been noted that the segment of Hospitals is
holding the largest share in the market. Antibody Drugs Industry is divided on
the basis of geography as North America, Southeast Asia, China, Europe, Japan,
and India.
Among
all the geographical regions, it has been observed that lately North America is
registering for the largest share in the Antibody Drugs Industry and it is
estimated that the region will go on dominating the market with the same pace,
the reason being augmented adoptions of modern technology, burgeoning demands,
improvements in the healthcare infrastructure, rising need for dealing with the
vital requirements, prerequisites treatment of cancer and various immunological
diseases like rheumatoid, augmented disposable income, and rise in the
healthcare expenditure among the consumers. In contrast, Asia Pacific is also
gradually showing a robust growth in the Antibody Drugs market due to
advancements in the healthcare sector and extended patient base in the region. The
leading companies that have contributed in the Antibody Drugs Market growth are
identified as Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche
Ltd., Eli Lilly and Co., Johnson & Johnson Services, Inc., AbbVie Inc., and
Amgen Inc.
Market Segment:
This report studies the global Antibody
Drugs market, analyzes and researches the Antibody Drugs development status and
forecast in United States, EU, Japan, China, India and Southeast Asia. This
report focuses on the top players in global market, like
•
Novartis
•
Amgen
•
Bristol-Myers Squibb
•
F. Hoffmann-La Roche
•
Johnson & Johnson
•
AbbVie
•
Eli Lilly
Market segment by Regions/Countries,
this report covers
•
United States
•
EU
•
Japan
•
China
•
India
•
Southeast Asia
Comments
Post a Comment